Browsing Tag
Ionis Pharmaceuticals
18 posts
Novartis and Ionis suffer pelacarsen setback as 8,000-patient heart trial misses endpoint
Novartis and Ionis Pharmaceuticals have suffered a major Phase III setback after pelacarsen successfully lowered lipoprotein(a) but failed to reduce cardiovascular events, challenging one of the most closely watched hypotheses in heart-drug development.
Novartis pelacarsen fails 8,323-patient Phase III test despite lowering Lp(a)
Novartis’ pelacarsen has failed the primary endpoint in the 8,323-patient Phase III Lp(a)HORIZON trial despite lowering lipoprotein(a), delivering a major setback to one of cardiovascular medicine’s most closely watched drug-development hypotheses and raising new questions for competing Lp(a)-lowering programmes.
Biogen stock (NASDAQ: BIIB) falls 8.2%: Can diranersen recover in Phase 3?
Biogen’s diranersen reduced tau and showed its strongest clinical result at the lowest dose, but the Phase 2 study missed its dose-response goal. With $BIIB down 8.2%, July 29 results and the Phase 3 design become the next tests.
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
AstraZeneca (AZN) shares fall as Wainua Phase III trial miss dents ATTR-CM growth hopes
Read how AstraZeneca’s Wainua trial miss reshapes AZN stock sentiment, ATTR-CM competition and its 2030 growth story after July 9.
Could elsunersen become the asset that steadies Praxis Precision Medicines’ CNS pipeline?
Find out how Praxis’ FDA Breakthrough Therapy Designation for elsunersen could affect PRAX stock, rare epilepsy strategy and precision neuroscience today!
Kardigan’s IPO demand looks strong, but the real test for KARD arrives in 2027
Kardigan raises $400 million in an upsized Nasdaq IPO to fund three cardiovascular trials. Discover the catalysts, cash runway and risks for KARD investors.
GSK’s bepirovirsen wins FDA priority review as chronic hepatitis B strategy enters decisive phase
GSK has FDA momentum in hepatitis B. The harder question is whether bepirovirsen can turn functional cure into a real market shift.
Kardigan’s tonlamarsen data put acute severe hypertension into sharper commercial focus
Kardigan’s tonlamarsen Phase 2 data showed blood pressure promise despite mixed endpoints. Read what it means for acute severe hypertension next.
Can zilganersen become the first disease-modifying therapy for Alexander disease?
Ionis wins FDA breakthrough therapy status for zilganersen in Alexander disease. Find out what this means for rare neurology drug development.